Trial reportThe journal of allergy and clinical immunology. In practice
Markers of Differential Response to Inhaled Corticosteroid Treatment Among Children with Mild Persistent Asthma.
Trial report in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.The Cochrane database of systematic reviews · 2021Pooled it
- Biomarkers to Predict Response to Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists in Adolescents and Adults with Mild Persistent Asthma.Annals of the American Thoracic Society · 2022Trial
- School-supervised use of a once-daily inhaled corticosteroid regimen: A cluster randomized trial.The Journal of allergy and clinical immunology · 2019Trial
- Frequency of Severe Asthma and Its Clinical Phenotypes at the Asthma Clinic in One of the Largest Sudanese Tertiary Pediatric Hospitals: A Cross-Sectional Hospital-Outpatient-Based Study.Journal of asthma and allergy · 2024Article
- Correlation BetweenReports of biochemistry & molecular biology · 2022Article
- Asthma and Allergy: Unravelling a Tangled Relationship with a Focus on New Biomarkers and Treatment.International journal of molecular sciences · 2022Review
- Sex and gender in asthma.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Treatment Response Biomarkers in Asthma and COPD.Diagnostics (Basel, Switzerland) · 2021Review
- Article
- Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease.Clinical reviews in allergy & immunology · 2019Review
- Asthma and Corticosteroid Responses in Childhood and Adult Asthma.Clinics in chest medicine · 2019Review
- A simple prediction tool for inhaled corticosteroid response in asthmatic children.BMC pulmonary medicine · 2017Article
- Personalized Medicine in Preschool Children with Asthma.Pediatric allergy, immunology, and pulmonology · 2017Article
- Glucocorticoid receptor expression on circulating leukocytes differs between healthy male and female adults.Journal of clinical and translational science · 2017Article
- Asthma biomarkers in the age of biologics.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 10 institutions in 1 country.
Funding
Abstract
backgroundInhaled corticosteroids are recommended as first-line therapy for children with mild persistent asthma; however, specific patient characteristics may modify the treatment response.
objectiveIdentify demographic, clinical, and atopic characteristics that may modify the inhaled corticosteroid treatment response among children enrolled in the Treating Children to Prevent Exacerbations of Asthma trial.
methodsChildren aged 6 to 18 years with mild persistent asthma were randomized to 44 weeks of combined, daily, rescue, or placebo treatment. Daily treatment consisted of 40 μg of beclomethasone twice daily. Rescue treatment consisted of 40 μg of beclomethasone accompanying each symptom-driven albuterol actuation. Combined treatment consisted of both. Outcomes included time to first exacerbation and proportion of asthma control days. Fourteen baseline characteristics were selected for interaction testing on the basis of their clinical relevance.
resultsTwo hundred eighty-eight children were randomized. Seventy-five percent were white, and 55% were male. As measured by time to first exacerbation, 4 characteristics identified children who received greater benefit from treatment: non-Hispanic ethnicity, positive aeroallergen skin test result, serum immunoglobulin E level of 350 K/μL or more, and history of oral corticosteroid use in the year before enrollment. As measured by asthma control days, 4 characteristics identified children who received greater benefit from treatment: male sex, positive aeroallergen skin test result, serum immunoglobulin E level of 350 K/μL or more, and incomplete run-in asthma control.
conclusionsChildren with mild persistent asthma who have markers of atopic asthma or who have greater asthma burden may obtain greater benefit from beclomethasone therapy. Additional study is needed to confirm whether these markers can guide individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.